Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate an improvement in Progression-Free
Survival (PFS) for the combination of vandetanib plus gemcitabine compared with gemcitabine
plus placebo in chemonaïve (not including an adjuvant regimen) patients aged ≥ 70 years with
advanced NSCLC.